Castle Biosciences - Castle BiosciencesDecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
MGM Resorts International Announces First Quarter Earnings Release Date
Credo and TE Connectivity Reach Settlement in Active Electrical Cable Disputes
Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
Tradeweb Announces Date for First Quarter 2026 Financial Results
Stratus Properties Inc. Reports Year Ended December 31, 2025 Results
United-Guardian Reports 2025 Financial Results
Planet Announces Redemption of Public Warrants
Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis